BIANCHINI, GIAMPAOLO

BIANCHINI, GIAMPAOLO  

Facoltà di Medicina e Chirurgia  

Mostra records
Risultati 1 - 20 di 99 (tempo di esecuzione: 0.035 secondi).
Titolo Data di pubblicazione Autore(i) File
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 1-gen-2012 Dutta, B; Pusztai, L; Qi, Y; André, F; Lazar, V; Bianchini, G; Ueno, N; Agarwal, R; Wang, B; Shiang, Cy; Hortobagyi, Gn; Mills, Gb; Symmans, Wf; Balázsi, G
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 1-gen-2014 Callari, M; Lembo, A; Bianchini, G; Musella, V; Cappelletti, V; Gianni, L; Daidone, Mg; Provero, P.
An unmet need: tailoring extended adjuvant endocrine therapy. 1-gen-2013 Bianchini, G; Gianni, L
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 1-gen-2016 Safonov, A; Wang, S; Gross, Cp; Agarwal, D; Bianchini, G; Pusztai, L; Hatzis, C.
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 1-gen-2017 Karn, T; Jiang, T; Hatzis, C; Sänger, N; El-Balat, A; Rody, A; Holtrich, U; Becker, S; Bianchini, G; Pusztai, L.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 1-gen-2022 Hurvitz, S. A.; Bachelot, T.; Bianchini, G.; Harbeck, N.; Loi, S.; Park, Y. H.; Prat, A.; Gilham, L.; Boulet, T.; Monturus, N. G. E.; Lambertini, C.; Nyawira, B.; Knott, A.; Restuccia, E.; Schmid, P.
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 1-gen-2012 Pietrantonio, Filippo; Biondani, Pamela; de Braud, Filippo; Pellegrinelli, Alessandro; Bianchini, Gianpaolo; Perrone, Federica; Formisano, Barbara; Di Bartolomeo, Maria
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 1-gen-2011 Iwamoto, T; Bianchini, G; Booser, D; Qi, Y; Coutant, C; Shiang, C; Santarpia, L; Matsuoka, J; Hortobagyi, Gn; Symmans, Wf; Holmes, F; O'Shaughnessy, J; Hellerstedt, B; Pippen, J; Andre, F; Simon, R; Pusztai, L
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 1-gen-2017 Bianchini, G; Kiermaier, A; Bianchi, Gv; Im, Yh; Pienkowski, T; Liu, Mc; Tseng, Lm; Dowsett, M; Zabaglo, L; Kirk, S; Szado, T; Eng-Wong, J; Amler, Lc; Valagussa, P; Gianni, L.
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 1-gen-2024 Dri, A.; Arpino, G.; Bianchini, G.; Curigliano, G.; Danesi, R.; De Laurentiis, M.; Del Mastro, L.; Fabi, A.; Generali, D.; Gennari, A.; Guarneri, V.; Santini, D.; Simoncini, E.; Zamagni, C.; Puglisi, F.
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 1-gen-2013 Kelly, Cm; Symmans, Wf; Andreopoulou, E; Bianchini, G
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 1-gen-2023 Licata, L.; Barreca, M.; Galbardi, B.; Dugo, M.; Viale, G.; Gyorffy, B.; Karn, T.; Pusztai, L.; Gianni, L.; Callari, M.; Bianchini, G.
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 1-gen-2021 Gelmon, K. A.; Fasching, P. A.; Couch, F. J.; Balmana, J.; Delaloge, S.; Labidi-Galy, I.; Bennett, J.; Mccutcheon, S.; Walker, G.; O'Shaughnessy, J.; Timcheva, C.; Tomova, A.; Eisen, A.; Lemieux, J.; Bazan, F.; Bourgeois, H.; Chakiba, C.; Chehimi, M.; Dalenc, F.; De La Motte Rouge, T.; Frenel, J. -S.; Goncalves, A.; Hardy-Bessard, A. C.; Lamy, R.; Levy, C.; Lortholary, A.; Mailliez, A.; Medioni, J.; Patsouris, A.; Spaeth, D.; Teixeira, L.; Tennevet, I.; Villanueva, C.; You, B.; Ettl, J.; Gerber, B.; Hoffmann, O.; Park-Simon, T. -W.; Reinisch, M.; Tio, J.; Wimberger, P.; Boer, K.; Ballestrero, A.; Bianchini, G.; Biganzoli, L.; Bordonaro, R.; Cognetti, F.; De Laurentiis, M.; De Placido, S.; Guarneri, V.; Montemurro, F.; Naso, G.; Santoro, A.; Zamagni, C.; Kim, S. -J.; Nakamura, S.; Chae, Y. S.; Cho, E. K.; Hyun, K. J.; Im, S. -A.; Lee, K. S.; Park, Y. H.; Sohn, J. H.; Byrski, T.; Huzarski, T.; Kukielka-Budny, B.; Nowecki, Z.; Szoszkiewicz, R.; Tarnawski, R.; Dvornichenko, V.; Moiseenko, F.; Mukhametshina, G.; Poddubskaya, E.; Popova, E.; Tarasova, A.; Vats, A.; Adamo, B.; Conejero, R. A.; Torres, A. A.; Gelpi, J. B.; Fernandez, N. D.; Gonzalez, A. F.; Garcia, J.; Lorenzo-Lorenzo, I.; Anton, F. M.; Santisteban, M.; Stradella, A.; Huang, C. -S.; Aksoy, S.; Arslan, C.; Artac, M.; Aydiner, A.; Ozyilkan, O.; Sezer, E.; Armstrong, A.; Barrett, S.; Borley, A.; Kemp, Z.; Michie, C.; Mukesh, M.; Perren, T.; Swampillai, A.; Young, T.
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 1-gen-2016 Ogiya, R; Niikura, N; Kumaki, N; Bianchini, G; Kitano, S; Iwamoto, T; Hayashi, N; Yokoyama, K; Oshitanai, R; Terao, M; Morioka, T; Tsuda, B; Okamura, T; Saito, Y; Suzuki, Y; Tokuda, Y.
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 1-gen-2022 Fabi, A.; Buono, G.; Bria, E.; Bianchini, G.; Curigliano, G.; De Laurentiis, M.; De Placido, S.; Del Mastro, L.; Guarneri, V.; Generali, D.; Livi, L.; Lorusso, V.; Montemurro, F.; Puglisi, F.; Vigneri, P.; Zambelli, A.; Arpino, G.
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 1-gen-2019 Hanker, A. B.; Estrada, M. V.; Bianchini, G.; Moore, P. D.; Zhao, J.; Cheng, F.; Koch, J. P.; Gianni, L.; Tyson, D. R.; Sanchez, V.; Rexer, B. N.; Sanders, M. E.; Zhao, Z.; Stricker, T. P.; Arteaga, C. L.
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 1-gen-2024 Dri, A.; Arpino, G.; Bianchini, G.; Curigliano, G.; Danesi, R.; De Laurentiis, M.; Del Mastro, L.; Fabi, A.; Generali, D.; Gennari, A.; Guarneri, V.; Santini, D.; Simoncini, E.; Zamagni, C.; Puglisi, F.
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 1-gen-2023 Miglietta, F.; Fabi, A.; Generali, D.; Dieci, M. V.; Arpino, G.; Bianchini, G.; Cinieri, S.; Conte, P. F.; Curigliano, G.; De Laurentiis, M.; Del Mastro, L.; De Placido, S.; Gennari, A.; Puglisi, F.; Zambelli, A.; Perrone, F.; Guarneri, V.
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 1-gen-2023 Miglietta, F.; Fabi, A.; Generali, D.; Dieci, M. V.; Arpino, G.; Bianchini, G.; Cinieri, S.; Conte, P. F.; Curigliano, G.; De Laurentiis, M.; Del Mastro, L.; De Placido, S.; Gennari, A.; Puglisi, F.; Zambelli, A.; Perrone, F.; Guarneri, V.
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 1-gen-2022 Garutti, M.; Griguolo, G.; Botticelli, A.; Buzzatti, G.; De Angelis, C.; Gerratana, L.; Molinelli, C.; Adamo, V.; Bianchini, G.; Biganzoli, L.; Curigliano, G.; De Laurentiis, M.; Fabi, A.; Frassoldati, A.; Gennari, A.; Marchio, C.; Perrone, F.; Viale, G.; Zamagni, C.; Zambelli, A.; Del Mastro, L.; De Placido, S.; Guarneri, V.; Marchetti, P.; Puglisi, F.